Bibliography from FDA Background Document September 23, 2004 VRBPAC Meeting:


1Meeting Summary: AIDS Vaccine Trials, Considerations for Phase III Trial Design and Endpoints.National Institutes of Health, NIAID, November 16, 2001.Retrieved from the World Wide Web on August 3, 2004 at


2NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed.NIAID News, February 25, 2002.Retrieved from the World Wide Web on August 9, 2004 at


3Burton DR, Desrosiers RC, Doms RW, et al.Public health.A sound rationale needed for phase III HIV-1 vaccine trials.Science 2004;303:316.


4McNeil JG, Johnston MI, Birx DL, Tramont EC.Policy rebuttal.HIV vaccine trial justified.Science 2004;303:961.


5Trinvuthipong, D.Thailandís prime-boost HIV vaccine trial phase III.Science 2004;303:954-5.


6Letters to the Editor.Science 2004;305:177-180.


7Tangcharoensathien V, Wiput P, Pitayarangsarit S, et al.The potential demand for an AIDS vaccine in Thailand.Health Policy 2001;57:111-139.


8Nitayaphan S, Pitisuttithum P, Karnasuta C, et al.Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.Journal of Infectious Diseases 2004;190:702-6.


9Tovanabutra S, et al.Characterization of full-length HIV-1 genomes from non-B subtype infections in U.S. military personnel.AIDS Vaccine 2003, New York, NY; Abstract number 463.


10McCarthy M.AIDS vaccine fails in Thai trial.Lancet. 2003 Nov 22;362(9397):1728.


11de Bruyn G, Rossini AJ, Chiu Y, et al.Safety profile of recombinant canarypox HIV vaccines.Vaccine 2004;22:704-13.


12Klausner RD, Fauci AS, Corey L, et al.The need for a global HIV vaccine enterprise.Science 2003;300:2036-39.